Rebecca Araujo

DocwireNews

A study presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024 reported results from a survey about the effects of burnout on oncology residency program directors (ORPDs). The survey showed that burnout is a continued challenge for program directors and aimed to highlight potential ways to mitigate the effects on oncology pharmacy education.The survey was sent to ORPDs listed in the ASHP Residency Directory in March 2023. Twenty-two questions covered aspects of the residency program, resources and time allocated to ORPDs, and scores on the Stanford Professional Fulfillment Index (PFI). Burnout was defined as PFI scores &ge;1.33.Sixty-one percent (n=35) of respondents had three years or fewer of ORPD experience. Regarding program characteristics, 70% had two or fewer residency slots, and 80% had at least one residency program coordinator. Fifty-six percent of programs had more than 10 preceptors, and 42% had a dedicated pharmacy education executive.ASHP Residency Standards require at least four hours per week of protected administration time for ORPDs to support residency training. According to the results of the survey, 50.8% of OPRDs felt that the ASHP standard did not provide them with sufficient time for administrative time and that more than four hours is consistently required (P=.013). In fact, only 17.5% reported receiving budgeted protected time as an incentive in their role, and 10% of respondents said they have more than four hours of budgeted protected time. Among patients who met the PFI burnout threshold, protected time or more protected time was the most important change to improve their well-being in more than 50% of respondents.&ldquo;Despite ASHP requirements, small numbers of ORPDs had budgeted protected time,&rdquo; the authors wrote. They added that respondents reported facing challenges with maintaining adequate clinical coverage.Regarding other ORPD position incentives, 15.7% of respondents reported receiving financial incentives, and 5.2% reported a combination of budgeted protected time and financial incentives. However, 61.5% of respondents did not report any incentives provided for the ORPD position. &ldquo;No specific demographic or incentive was significantly linked with likelihood of well-being, PFI, burnout, or considering stepping down,&rdquo; the authors wrote. Seventy percent of respondents reported thinking of stepping down from their roles in the previous 12 months, with greater rates among ORPDs with fewer years of experience.&ldquo;ORPDs consistently rank protected time as being impactful&rdquo; on addressing burnout and improving fulfilment, the authors wrote. They also noted that other resources, such as residency program coordinators and financial incentives, were valued by respondents. &ldquo;Providing appropriate resources to ORPDs is essential.&rdquo;<h4>Reference</h4>Przespolewski ER, Abdel-Razzaq A, Falls SM, Riebandt G. Survey of PGY-2 oncology residency program directors to assess resources and effects on burnout. Poster. Presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024; April 3-6, 2024; Tampa, Florida.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Oncology Residency Program Directors Rate Protected Time as Essential to Address Burnout

HOPA Annual Conference 2024

More than half of oncology residency program directors surveyed rated protective administrative time as the most important change to improve their well-being. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe